#USA #Chicago #Life Sciences #EVERSANA #AI Accelerator

EVERSANA AI Accelerator: A New Era in Life Sciences Commercialization

In a significant development for the life sciences industry, EVERSANA, a renowned provider of commercialization services, has launched the EVERSANA AI Accelerator. This dedicated Center of Excellence aims to harness artificial intelligence (AI) to revolutionize various aspects of commercialization in the life sciences segment.

Led by Faruk Capan, EVERSANA's Chief Innovation Officer, the AI Accelerator is focused on reimagining how drugs are priced, promoted, accessed, and delivered globally. By leveraging advanced AI research and transformative services, EVERSANA is committed to changing the way pharmaceutical commercialization operates. Jim Lang, the CEO of EVERSANA, emphasized the importance of this initiative, stating, "Patients have waited far too long to reap the benefits of what's possible when pharma commercialization is propelled by AI."

The Value of AI in Pharmaceuticals

According to the McKinsey Global Institute (MGI), generative AI could add between $60 billion to $110 billion in annual value throughout the pharmaceutical value chain, with commercialization alone accounting for $18 billion to $30 billion of that total. This highlights the transformative potential that AI holds not just for EVERSANA but for the entire pharmaceutical sector.

Key Features of the EVERSANA AI Accelerator

The EVERSANA AI Accelerator operates through several core components designed to support its goals:

1. Expert AI and Commercialization Teams: The Accelerator boasts a team of AI innovators collaborating with leaders in the life sciences to tackle complex challenges such as global drug pricing, promotional strategies, and access to healthcare.

2. Strategic Technology Partnerships: EVERSANA has formed partnerships with leading technology giants such as Amazon Web Services, Google, Salesforce, and Veeva. These collaborations aim to integrate cutting-edge technological solutions into life sciences commercialization strategies.

3. Engagement with Pharmaceutical Innovators: The Accelerator is actively engaging with pharmaceutical and medical device companies, including startups that are pioneering new AI platforms and tools.

4. Deploying Advanced Technologies: One notable deployment from the Accelerator is EVERSANA ORCHESTRATE MLR, an AI-driven Medical, Legal, and Regulatory platform recognized for its innovation with an Emerald Pinnacle Technology Award.

The Future of Life Sciences

The innovations stemming from the EVERSANA AI Accelerator are currently in beta testing, focusing on improvements in pharmaceutical marketing, patient support services, and comprehensive commercialization operations. This initiative reflects EVERSANA's long-standing commitment to transformative change, echoing its earlier innovations such as the COMPLETE Commercialization model.

"Innovation isn't new to EVERSANA. Today, we give that spirit of transformation a home in our global enterprise," stated Jim Lang. This call for collaboration signifies an invitation for partners and clients to come together and shape the future of life sciences commercialization, maximizing the potential of AI for a healthier world.

Conclusion

As EVERSANA embarks on this exciting journey with the AI Accelerator, it sets a precedent in the life sciences industry, blending advanced technology with a keen understanding of patient needs. The potential benefits of this initiative promise not only to enhance operational efficiencies but also to ultimately improve patient outcomes—a vision that the entire sector should rally around.

To explore more about the EVERSANA AI Accelerator or to initiate partnerships and collaborations, visit eversana.ai.

• ---